The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
Cancer.
2024 May 15;130(10):1766-1772. doi: 10.1002/cncr.35215. Epub 2024 Jan 27. PubMed PMID:
38280206.
"It Gives Me Peace of Mind So I Can Focus on Healing": Views on Advance Care Planning for Older Surgical Patients.
J Palliat Med.
2024 Feb 20;. doi: 10.1089/jpm.2023.0589. [Epub ahead of print] PubMed PMID:
38386513.
Gender Bias in Letters of Recommendation: Relevance to Urology Match Outcomes and Pursuit of Fellowship Training/Academic Career.
Urology.
2024 Jan;183:281-287. doi: 10.1016/j.urology.2023.09.053. Epub 2023 Nov 7. PubMed PMID:
37940078.
Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
Eur Urol.
2023 Oct 17;. doi: 10.1016/j.eururo.2023.09.024. [Epub ahead of print] PubMed PMID:
37858454.
Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer.
Urol Oncol.
2023 Oct;41(10):429.e9-429.e14. doi: 10.1016/j.urolonc.2023.06.003. Epub 2023 Jul 3. PubMed PMID:
37407420.
Ten-year work burden after prostate cancer treatment.
Cancer Med.
2023 Sep;12(18):19234-19244. doi: 10.1002/cam4.6530. Epub 2023 Sep 19. PubMed PMID:
37724617; PubMed Central PMCID:
PMC10557888.
The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer.
Urology.
2023 Aug;178:114-119. doi: 10.1016/j.urology.2023.05.012. Epub 2023 May 25. PubMed PMID:
37244430.
Post-diagnostic health behaviour scores and risk of prostate cancer progression and mortality.
Br J Cancer.
2023 Aug;129(2):346-355. doi: 10.1038/s41416-023-02283-1. Epub 2023 May 22. PubMed PMID:
37217583; PubMed Central PMCID:
PMC10338438.
Controlled trial of decision support for men with early-stage prostate cancer: brief research report of effects on patient knowledge.
Front. Urol.. 2023 May; 3:1127089. doi: 10.3389/fruro.2023.1127089.
Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula.
Eur J Epidemiol.
2022 Dec;37(12):1205-1213. doi: 10.1007/s10654-022-00929-7. Epub 2022 Oct 26. PubMed PMID:
36289138.
Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.
Eur J Cancer Care (Engl).
2022 Nov;31(6):e13740. doi: 10.1111/ecc.13740. Epub 2022 Oct 14. PubMed PMID:
36239065.
Postdiagnostic Inflammatory, Hyperinsulinemic, and Insulin-Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality.
Cancer Epidemiol Biomarkers Prev.
2022 Sep 2;31(9):1760-1768. doi: 10.1158/1055-9965.EPI-22-0147. PubMed PMID:
35767977; PubMed Central PMCID:
PMC9444922.
See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
Global Surgical Education - Journal of the Association for Surgical Education. 2022 August; 1(1):36.
Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
J Urol.
2022 Apr;207(4):832-840. doi: 10.1097/JU.0000000000002335. Epub 2021 Dec 2. PubMed PMID:
34854749.
Advanced Practice Provider Perspectives on Advanced Care Planning.
Journal of Clinical and Translational Science. 2022; 6(S1):75-76. doi: 10.1017/cts.2022.227.
Patient Perceptions on Barriers and Facilitators to Accessing Low-acuity Surgery During COVID-19 Pandemic.
J Surg Res.
2021 Aug;264:30-36. doi: 10.1016/j.jss.2021.01.028. Epub 2021 Feb 6. PubMed PMID:
33744775; PubMed Central PMCID:
PMC7867400.
Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history.
Cancer Causes Control.
2021 Jun;32(6):635-644. doi: 10.1007/s10552-021-01417-1. Epub 2021 Apr 9. PubMed PMID:
33837499; PubMed Central PMCID:
PMC8189293.
Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial.
J Med Internet Res.
2020 Dec 31;22(12):e19238. doi: 10.2196/19238. PubMed PMID:
33382378; PubMed Central PMCID:
PMC7808895.
Web-Based Lifestyle Interventions for Prostate Cancer Survivors: Qualitative Study.
JMIR Cancer.
2020 Nov 10;6(2):e19362. doi: 10.2196/19362. PubMed PMID:
33170126; PubMed Central PMCID:
PMC7685923.
Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Urol Oncol.
2020 Oct;38(10):793.e1-793.e11. doi: 10.1016/j.urolonc.2020.07.012. Epub 2020 Aug 8. PubMed PMID:
32782182.
The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer.
JNCI Cancer Spectr.
2020 Oct;4(5):pkaa044. doi: 10.1093/jncics/pkaa044. eCollection 2020 Oct. PubMed PMID:
33134826; PubMed Central PMCID:
PMC7583149.
Web-Based Lifestyle Interventions for Prostate Cancer Survivors: Qualitative Study (Preprint). [preprint]. 2020 April. doi: 10.2196/preprints.19362.
Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry.
Clin Genitourin Cancer.
2020 Feb;18(1):e21-e27. doi: 10.1016/j.clgc.2019.10.026. Epub 2019 Nov 6. PubMed PMID:
31796344.
Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients.
Cancer Med.
2020 Jan;9(1):125-132. doi: 10.1002/cam4.2685. Epub 2019 Nov 12. PubMed PMID:
31714037; PubMed Central PMCID:
PMC6943165.
Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.
Eur Urol.
2019 Dec;76(6):743-751. doi: 10.1016/j.eururo.2019.07.012. Epub 2019 Jul 23. PubMed PMID:
31345635.
Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.
Cancer Epidemiol Biomarkers Prev.
2019 Nov;28(11):1917-1925. doi: 10.1158/1055-9965.EPI-19-0488. Epub 2019 Aug 28. PubMed PMID:
31462398; PubMed Central PMCID:
PMC6825577.
What Matters? The Valued Life Activities of Older Adults Undergoing Elective Surgery.
J Am Geriatr Soc.
2019 Nov;67(11):2305-2310. doi: 10.1111/jgs.16102. Epub 2019 Aug 10. PubMed PMID:
31400227; PubMed Central PMCID:
PMC6910083.
Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer.
J Urol.
2019 Oct;202(4):689-695. doi: 10.1097/JU.0000000000000336. Epub 2019 Sep 6. PubMed PMID:
31091175; PubMed Central PMCID:
PMC7017721.
Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.
Urology.
2019 Sep;131:157-165. doi: 10.1016/j.urology.2019.05.018. Epub 2019 May 28. PubMed PMID:
31150694.
Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
Prostate Cancer Prostatic Dis.
2019 Mar;22(1):117-124. doi: 10.1038/s41391-018-0084-3. Epub 2018 Aug 31. PubMed PMID:
30171230.
Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc.
2018 Nov 15;7(11):e11257. doi: 10.2196/11257. PubMed PMID:
30442638; PubMed Central PMCID:
PMC6265599.
Increasing Advance Care Planning Using a Surgical Optimization Program for Older Adults.
J Am Geriatr Soc.
2018 Oct;66(10):2017-2021. doi: 10.1111/jgs.15554. Epub 2018 Oct 5. PubMed PMID:
30289968; PubMed Central PMCID:
PMC6181775.
Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™).
Prostate.
2018 Jan;78(1):32-39. doi: 10.1002/pros.23441. Epub 2017 Nov 6. PubMed PMID:
29105845; PubMed Central PMCID:
PMC5716878.
Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.
J Urol.
2017 Sep;198(3):671-677. doi: 10.1016/j.juro.2017.03.121. Epub 2017 Mar 22. PubMed PMID:
28342935; PubMed Central PMCID:
PMC5636214.
National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United States.
Urology Practice. 2014 November; 1(4):198-204. doi: 10.1016/j.urpr.2014.07.005.
Sustainable Measurement of Response Shift in Prostate Cancer Patients: Adjusting Health Related Quality of Life with the Then-Test.
Value Health.
2014 Nov;17(7):A651. doi: 10.1016/j.jval.2014.08.2366. Epub 2014 Oct 26. PubMed PMID:
27202352.
Measurement equivalence using a mixed-mode approach to administer health-related quality of life instruments.
Qual Life Res.
2014 Mar;23(2):495-508. doi: 10.1007/s11136-013-0493-7. Epub 2013 Aug 13. PubMed PMID:
23943258.
- Data quality with mixed-mode administration of the short form-36.
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014; 17(3):A198.
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
Cancer.
2010 Nov 15;116(22):5226-34. doi: 10.1002/cncr.25456. PubMed PMID:
20690197; PubMed Central PMCID:
PMC2975879.
Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.
Am J Clin Nutr.
2010 Mar;91(3):712-21. doi: 10.3945/ajcn.2009.28474. Epub 2009 Dec 30. PubMed PMID:
20042525; PubMed Central PMCID:
PMC3132069.
Time trends and local variation in primary treatment of localized prostate cancer.
J Clin Oncol.
2010 Mar 1;28(7):1117-23. doi: 10.1200/JCO.2009.26.0133. Epub 2010 Feb 1. PubMed PMID:
20124165; PubMed Central PMCID:
PMC2834465.
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
J Clin Oncol.
2009 Sep 10;27(26):4306-13. doi: 10.1200/JCO.2008.21.5228. Epub 2009 Aug 10. PubMed PMID:
19667269; PubMed Central PMCID:
PMC2744272.
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
J Natl Cancer Inst.
2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9. PubMed PMID:
19509351; PubMed Central PMCID:
PMC2697208.
High-risk prostate cancer in the United States, 1990-2007.
World J Urol.
2008 Jun;26(3):211-8. doi: 10.1007/s00345-008-0250-7. Epub 2008 Mar 28. PubMed PMID:
18369637; PubMed Central PMCID:
PMC2948572.
Longitudinal comparison across treatments, risk and age of work loss costs in prostate cancer patients: 10-year patterns.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008; 11(3):A68-9. doi: 10.1016/S1098-3015(10)70226-6.
Contemporary trends in low risk prostate cancer: risk assessment and treatment.
J Urol.
2007 Sep;178(3 Pt 2):S14-9. doi: 10.1016/j.juro.2007.03.135. Epub 2007 Jul 20. PubMed PMID:
17644125; PubMed Central PMCID:
PMC2987559.
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice.
Cancer.
2007 May 1;109(9):1777-83. doi: 10.1002/cncr.22615. PubMed PMID:
17354226.
Cumulative cost pattern comparison of prostate cancer treatments.
Cancer.
2007 Feb 1;109(3):518-27. doi: 10.1002/cncr.22433. PubMed PMID:
17186528.
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE.
J Urol.
2006 Apr;175(4):1326-31. doi: 10.1016/S0022-5347(05)00647-6. PubMed PMID:
16515991.
Validation of an Internet-base Patient Health-Related Quality of Life Questionnaire: Data from CaPSURE.
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2006; 9(3):A114.
What would you like to do?